Omnicell (OMCL) AI Stock Analysis

• Market Cap: $1.45B
• Dividend Yield: N/A
• Average Volume (3M): 555.84K
• Price to Earnings (P/E): 64.7
• Beta (1Y): 0.35
• Revenue Growth: 6.39%
• EPS Growth: N/A
• Country: US
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.45
• Shares Outstanding: 45,934,250
• 10 Day Avg. Volume: 577,840
• 30 Day Avg. Volume: 555,840
• PEG Ratio: -1.02
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 1.84
• P/FCF Ratio: 13.55
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 1.16
• Enterprise Value/Gross Profit: 2.65
• Enterprise Value/Ebitda: 14.23
• 1Y Price Target: $41.75
• Price Target Upside: 30.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 66 Neutral
• Price Target: $34.00 ▲(6.55% Upside)

Omnicell's overall stock score is driven by strong earnings call performance and positive corporate events, including a stock buyback program. However, the high P/E ratio and lack of technical analysis data weigh down the score. Financial performance is stable but unremarkable, with challenges in revenue growth and operational efficiency.

Positive Factors

Financial Performance

The company achieved higher-than-expected revenue and adjusted EBITDA, surpassing guidance and consensus estimates.

Strategic Initiatives

Omnicell is taking steps to mitigate the tariff impact by sourcing components from lower tariff geographies.

Tariff Conditions

A potential post-pause tariff rate of 55% implies a favorable scenario for Omnicell, leading to significant savings.

Negative Factors

CapEx Outlook

The broader CapEx outlook weakened for the second consecutive quarter as uncertainty around tariffs and legislation appear to be impacting spend.

Market Uncertainty

Limited visibility into components of product revenue growth creates uncertainty near-term.

Tariff Impact

The ever-changing tariff backdrop, particularly with China, has led to two guidance revisions and significant stock price volatility.

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc. is a leading healthcare technology company that specializes in medication management solutions and supply chain automation for hospitals and other healthcare facilities. Established to enhance patient safety and streamline pharmacy operations, Omnicell offers a range of products including automated dispensing systems, medication adherence solutions, and analytics software. The company primarily operates in the healthcare sector and serves various healthcare providers by optimizing medication delivery and inventory management.

How the Company Makes Money

Omnicell generates revenue through several key streams, primarily by selling its automated medication management systems and related services to healthcare providers. The company offers a subscription-based model for its software solutions, which provides ongoing revenue through software licenses and support services. Additionally, Omnicell benefits from recurring revenue through maintenance contracts and upgrades for its hardware systems. Strategic partnerships with healthcare organizations and technology providers further enhance its market reach and contribute to its earnings. The company also invests in research and development to innovate its product offerings, ensuring they meet the evolving needs of the healthcare sector, which can lead to increased sales and market penetration.

Omnicell Financial Statement Overview

Summary

Omnicell's financials reflect a stable yet unremarkable performance. The company maintains healthy profit margins and a stable equity base, but faces challenges in revenue growth and operational efficiency. Cash flow generation remains strong, providing a cushion against potential downturns. However, the decline in free cash flow growth could pose a risk if not addressed.

Income Statement

The company shows a mixed performance in its income statement. The TTM Gross Profit Margin is 43.7%, indicating good control over production costs. However, the Net Profit Margin is low at 2.0%, highlighting challenges in managing other operating expenses. Revenue has decreased when comparing the recent annual figures, showing a decline of 12.1% from 2022 to 2023. EBIT and EBITDA margins in the TTM are also low, at 1.3% and 5.2% respectively, indicating low operational efficiency.

Balance Sheet

The balance sheet indicates a moderate financial position. The Debt-to-Equity Ratio stands at 0.29, suggesting a manageable level of debt relative to equity. The Return on Equity (ROE) for the TTM is 1.8%, which is relatively low but positive. The Equity Ratio is healthy at 58.9%, showing a strong equity base relative to total assets, contributing to financial stability.

Cash Flow

Cash flow statements reveal a positive outlook, with a TTM Operating Cash Flow to Net Income Ratio of 6.4, indicating robust cash generation relative to net income. However, the Free Cash Flow Growth Rate from the previous annual report is negative at -32.3%, indicating a decline in free cash flow. The Free Cash Flow to Net Income Ratio is 4.4, showing good cash flow coverage of net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.15B	1.11B	1.15B	1.30B	1.13B	892.21M
Gross Profit	502.64M	471.00M	499.93M	588.99M	554.65M	413.29M
EBITDA	93.75M	90.09M	60.69M	96.85M	174.44M	107.12M
Net Income	23.09M	12.53M	-20.37M	5.65M	77.85M	32.19M
Balance Sheet
Total Assets	2.15B	2.12B	2.23B	2.21B	2.14B	1.82B
Cash, Cash Equivalents and Short-Term Investments	399.00M	381.68M	467.97M	330.36M	349.05M	485.93M
Total Debt	372.56M	382.55M	614.09M	616.74M	528.06M	516.10M
Total Liabilities	881.88M	877.65M	1.04B	1.08B	995.81M	857.00M
Stockholders Equity	1.26B	1.24B	1.19B	1.13B	1.15B	967.50M
Cash Flow
Free Cash Flow	102.37M	151.26M	126.08M	17.04M	173.47M	131.00M
Operating Cash Flow	147.75M	187.72M	181.09M	77.78M	231.81M	185.87M
Investing Cash Flow	-58.57M	-52.79M	-55.02M	-58.67M	-412.50M	-279.87M
Financing Cash Flow	-238.31M	-235.58M	23.42M	-20.95M	47.36M	456.27M

Omnicell Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Positive. The current price of 31.91 is above the 20-day moving average (MA) of 30.40, above the 50-day MA of 29.57, and below the 200-day MA of 36.37, indicating a neutral trend. The MACD of 0.72 indicates Negative momentum. The RSI at 65.44 is Neutral, neither overbought nor oversold. The STOCH value of 69.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OMCL.

Omnicell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHR	71 Outperform	$1.73B	―	-15.97%	―	16.29%	66.01%
HSTM	69 Neutral	$790.83M	40.10	5.81%	0.46%	3.50%	13.99%
OMCL	66 Neutral	$1.45B	64.69	1.87%	―	6.39%	―
PINC	61 Neutral	$2.01B	111.05	3.56%	3.20%	-24.79%	-78.38%
Sector *	57 Neutral	£5.39B	4.80	-44.55%	2.30%	28.89%	-10.08%
SDGR	50 Neutral	$1.48B	―	-44.40%	―	18.59%	10.96%
TDOC	48 Neutral	$1.33B	―	-14.18%	―	-2.57%	79.86%

Omnicell Corporate Events

Omnicell CFO Nchacha Etta to Step Down

Omnicell, Inc. announced that its Chief Financial Officer, Nchacha Etta, will step down from his role effective September 15, 2025, or until a successor is named. The company has entered into a separation agreement with Mr. Etta, extending his separation date to November 15, 2025, and outlining terms for his continued service and benefits, including a severance payment, bonus eligibility, and additional vesting credit for equity awards.

The most recent analyst rating on (OMCL) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.

Omnicell Stockholders Approve Key Proposals at Annual Meeting

On May 21, 2025, Omnicell, Inc. held its Annual Meeting where stockholders voted on several key proposals. Three directors, Edward P. Bousa, Mary Garrett, and Bruce E. Scott, were elected to the Board until 2028. The stockholders also approved executive officer compensation and an amendment to the 2009 Equity Incentive Plan, which includes an additional 1,750,000 shares for issuance. Additionally, Deloitte & Touche LLP was ratified as the independent accounting firm for 2025.

The most recent analyst rating on (OMCL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.

Omnicell Updates 2025 Guidance and Stock Buyback Plan

On May 22, 2025, Omnicell announced an update to its second quarter and full-year 2025 guidance, reflecting improved profitability due to reduced tariff rates on imports from China. The company also introduced a new $75 million stock repurchase program, indicating confidence in its financial health and commitment to delivering innovative medication management solutions.

The most recent analyst rating on (OMCL) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.